Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Gains from Sales and Divestitures (2016 - 2020)

Celldex Therapeutics (CLDX) has 9 years of Gains from Sales and Divestitures data on record, last reported at $1110.0 in Q4 2020.

  • For Q4 2020, Gains from Sales and Divestitures fell 50.0% year-over-year to $1110.0; the TTM value through Dec 2020 reached $1110.0, down 50.0%, while the annual FY2020 figure was $1110.0, 50.0% down from the prior year.
  • Gains from Sales and Divestitures reached $1110.0 in Q4 2020 per CLDX's latest filing, down from $2220.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $19500.0 in Q4 2016 and bottomed at $1110.0 in Q4 2020.
  • Average Gains from Sales and Divestitures over 5 years is $8388.8, with a median of $2449.0 recorded in 2018.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 85.3% in 2018, then fell 9.35% in 2019.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $19500.0 in 2016, then fell by 14.54% to $16665.0 in 2017, then plummeted by 85.3% to $2449.0 in 2018, then dropped by 9.35% to $2220.0 in 2019, then tumbled by 50.0% to $1110.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1110.0 in Q4 2020, $2220.0 in Q4 2019, and $2449.0 in Q4 2018.